481038-63-5

Basic information

• Product Name: 1-N-Boc-2-Benzylpiperazine
• Synonyms: N-1-BOC-2-BENZYL PIPERAZINE;2-BENZYL-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER;1-N-Boc-2-benzylpiperazine;1-Boc-2-benzyl-piperazine;N-1-BOC-2-BENZYL PIPERIZINE;1-N-Boc-2-benzylpiperizine;1-N-Boc-2-Benzyl;TERT-BUTYL2-BENZYLPIPERAZINE-1-CARBOXYLATE
• CAS NO: 481038-63-5
• Molecular Formula: C16H24N2O2
• Molecular Weight: 276.37
• Product Categories: Pyrans, Piperidines &Piperazines;Piperaizine;Pyrans, Piperidines & Piperazines
• Mol File: 481038-63-5.mol

Chemical Properties

• Boiling Point: 382.9 °C at 760 mmHg
• Flash Point: 185.4 °C
• Appearance: /
• Density: 1.066 g/cm³
• Vapor Pressure: 4.58E-06mmHg at 25°C
• Refractive Index: 1.524
• Storage Temp.: 2-8°C
• PKA: 8.45±0.40(Predicted)
• CAS DataBase Reference: 1-N-Boc-2-Benzylpiperazine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-N-Boc-2-Benzylpiperazine(481038-63-5)
• EPA Substance Registry System: 1-N-Boc-2-Benzylpiperazine(481038-63-5)

Safety Data

• Hazardous Substances Data: 481038-63-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-N-Boc-2-Benzylpiperazine is used as a reactant for the preparation of 1-(4-aryl-3-aminobutanoyl)piperazines, which are dipeptidyl peptidase inhibitors. These inhibitors play a crucial role in the treatment of diabetes mellitus by regulating the levels of glucose in the body.
Application Reason:
The use of 1-N-Boc-2-Benzylpiperazine in the synthesis of dipeptidyl peptidase inhibitors is due to its ability to provide a stable and functional intermediate that can be further modified to develop potent and selective inhibitors. These inhibitors can help manage blood sugar levels in diabetic patients, making it an essential component in the development of novel therapeutics for diabetes management.

InChI:InChI=1/C16H24N2O2/c1-16(2,3)20-15(19)18-10-9-17-12-14(18)11-13-7-5-4-6-8-13/h4-8,14,17H,9-12H2,1-3H3

Upstream product

• 489437-72-1 1-tert-Butoxycarbonyl-2(S)-(S),4-dibenzylpiperazine 
• 13734-34-4 N-tert-butoxycarbonyl-L-phenylalanine 
• 169447-84-1 (3S)-1,3-dibenzylpiperazine-2,5-dione 
• 204327-96-8 (3S)-1,3-dibenzylpiperazine 

Downstream Products

• 956006-06-7 2-amino-3-[(S)-4-Boc-3-benzylpiperazinyl]-5-(3-methyl-1H-indazol-5-yl)pyrazine 
• 956006-16-9 2-[(S)-4-Boc-3-benzylpiperazinyl]-6-[3-methyl-1-(2-(trimethylsilyl)ethoxymethyl)-1H-indazol-5-yl]pyrazine 

Relevant articles and documents

Efficient one-pot synthesis of enantiomerically pure: N -protected-α-substituted piperazines from readily available α-amino acids

A new pathway towards enantiomerically pure 3-substituted piperazines, bearing a benzyl protecting group, has been developed in good overall yields (83-92%), starting from commercially available N-protected amino acids. The methodology represents an efficient and simple one-pot procedure, employing a synthetic sequence consisting of an Ugi-4 component reaction, a Boc-deprotection, an intramolecular cyclisation reaction and a final reduction (UDCR). From the benzyl protected precursors, the 2-substituted piperazines bearing a Boc-protecting group could consequently also be obtained via a simple protection and deprotection step of the corresponding piperazines. The practical utility of this methodology was demonstrated for chiral drug synthesis.

Therapeutic Piperazines

The invention includes a compound of formula I: wherein R1, X, Z, n, and m have any of the values described herein, as well as salts of such compounds, compositions comprising such compounds, and therapeutic methods that comprise the administra

INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE

The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras

Inhibitors of farnesyl-protein transferase

The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras. The compounds of formula A are representative of the compounds of the present invention: STR1